Smart tags and a phone app could boost hepatitis c treatment success

NCT ID NCT06263829

Completed Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a smartphone app called Tappt that uses smart tags to help people with hepatitis C stick to their daily oral medication. Participants scan tags each time they take a dose, and the app tracks adherence. The study compares their results to historical data from similar patients. The goal is to see if this simple digital tool improves medication completion and cure rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tappt app (digital medication companion with smart tags)
What this could lead to: If effective, this approach could help more people with hepatitis C complete their treatment and achieve a cure, while giving pharmacists better tools to personalize care.
What could go wrong: This is a very small pilot study (5 participants) with no blinding or randomization, so results may not apply broadly. The app relies on consistent smartphone use, which may not suit everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C

Contacts and locations

Locations

UIH

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.